Verition Fund Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Verition Fund Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-17,500	Closed	-$1.44M	–	3202
2024 Q2	$1.44M	Sell	17,500 -6,400	-27%	-$533K	0.01%	1454
2024 Q1	$2.09M	Buy	23,900 +18,000	+305%	+$1.61M	0.01%	1185
2023 Q4	$569K	Buy	+5,900	New	+$522K	﹤0.01%	1456
2023 Q2	–	Sell	-10,200	Closed	-$992K	–	2219
2023 Q1	$992K	Buy	+10,200	New	+$1.06M	0.01%	955
2021 Q3	–	Sell	-5,000	Closed	-$417K	–	1922
2021 Q2	$417K	Buy	+5,000	New	+$396K	﹤0.01%	1177
2020 Q1	–	Sell	-7,700	Closed	-$651K	–	641
2019 Q4	$651K	Buy	+7,700	New	+$582K	0.01%	579
2019 Q2	–	Sell	-35,900	Closed	-$3.19M	–	1076
2019 Q1	$3.19M	Buy	35,900 +15,500	+76%	+$1.44M	0.12%	115
2018 Q4	$1.74M	Buy	+20,400	New	+$1.94M	0.12%	149

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Verition Fund Management's BMRN Position: Q1 2026 in Review

Verition Fund Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 86,600 shares — an estimated $5.15M sold.

Verition Fund Management first reported a position in BMRN in Q2 2013 and held it in 38 quarters. The position peaked at $22M in Q2 2022. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Verition Fund Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Verition Fund Management sold 86,600 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $5.15M.
Verition Fund Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 38 quarters.
Verition Fund Management's BioMarin Pharmaceuticals position peaked at $22M in Q2 2022.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.